Advertisement

Daré Bioscience, Inc. DARE

Set alert

Price alert · DARE

All alert types
0.70 USD +0.02 +2.66%

At close · Oct 30

0.67 -0.03 -4.16%

After hours · Oct 30, 7:24 PM ET

Bid
0.69 × 2
Ask
0.70 × 10
0.67 Day range 0.7026
0.644 52-week range 3.27
YTD
-63.75%
1 year
-63.75%
Open
0.7026
Prev close
0.6815
Mkt cap
13.76M
Vol
654.01K
Avg vol
496.64K
EPS
-0.71
P/E
0.00
Div yield
0.00%
More statistics
Low
0.67
High
0.7026
Forward P/E
-2.35
Beta
1.34
Short ratio
0.64
Inst. own
7.59%
Dividend
0.00
Ex-div date
50-d avg
3.53
200-d avg
4.07
1y target
21.33

2Y chart

Chart tools
Interval

Events in this range
  • Nov 14, 2024Earnings: -0.55; estimate -0.6; surprise 8.33%
  • Nov 15, 2024Rating: HC Wainwright & Co. · Buy → Buy
  • Dec 17, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (80)
NameDateAgo
MACD: Buy SignalOct 30, 20262 days ago
RSI: OversoldOct 22, 20261 week ago
MACD: Sell SignalOct 16, 20262 weeks ago
MACD: Buy SignalAug 31, 20262 months ago
MACD: Sell SignalAug 17, 20262 months ago
RSI: OversoldAug 14, 20262 months ago
MACD: Buy SignalAug 5, 20262 months ago
RSI: OversoldJul 20, 20263 months ago
SMA: BearishJul 16, 20263 months ago
MACD: Sell SignalJul 16, 20263 months ago
MACD: Buy SignalJun 17, 20264 months ago
SMA: BullishJun 16, 20264 months ago
SMA: BearishJun 15, 20264 months ago
SMA: BullishJun 10, 20264 months ago
SMA: BearishJun 5, 20264 months ago
SMA: BearishJun 1, 20265 months ago
MACD: Sell SignalMay 12, 20265 months ago
MACD: Buy SignalMay 4, 20266 months ago
RSI: OverboughtMay 4, 20266 months ago
MACD: Sell SignalApr 27, 20266 months ago
SMA: BullishApr 16, 20266 months ago
RSI: OverboughtApr 16, 20266 months ago
RSI: OverboughtApr 1, 20267 months ago
SMA: BullishMar 30, 20267 months ago
MACD: Buy SignalMar 26, 20267 months ago
RSI: OversoldMar 17, 20267 months ago
RSI: OversoldMar 12, 20267 months ago
RSI: OversoldMar 10, 20267 months ago
MACD: Sell SignalMar 4, 20268 months ago
MACD: Buy SignalFeb 24, 20268 months ago
SMA: BearishJan 28, 20269 months ago
SMA: BullishJan 27, 20269 months ago
SMA: BearishJan 23, 20269 months ago
SMA: BullishJan 22, 20269 months ago
SMA: BearishJan 21, 20269 months ago
SMA: BullishJan 20, 20269 months ago
SMA: BearishJan 16, 20269 months ago
SMA: BullishJan 14, 20269 months ago
MACD: Sell SignalDec 29, 202510 months ago
SMA: BearishDec 15, 202510 months ago
SMA: BullishDec 12, 202510 months ago
RSI: OverboughtDec 12, 202510 months ago
SMA: BullishDec 10, 202510 months ago
MACD: Buy SignalNov 26, 202511 months ago
RSI: OversoldNov 20, 202511 months ago
MACD: Sell SignalNov 17, 202511 months ago
MACD: Buy SignalNov 12, 202511 months ago
SMA: BearishOct 27, 20251 year ago
SMA: BullishOct 24, 20251 year ago
SMA: BearishOct 22, 20251 year ago
SMA: BullishOct 21, 20251 year ago
SMA: BearishOct 17, 20251 year ago
SMA: BullishOct 16, 20251 year ago
SMA: BearishOct 14, 20251 year ago
MACD: Sell SignalOct 14, 20251 year ago
MACD: Buy SignalAug 21, 20251 year ago
RSI: OversoldAug 7, 20251 year ago
MACD: Sell SignalJul 30, 20251 year ago
SMA: BearishJul 16, 20251 year ago
SMA: BullishJul 14, 20251 year ago
MACD: Buy SignalJul 14, 20251 year ago
RSI: OversoldJun 27, 20251 year ago
RSI: OversoldJun 23, 20251 year ago
SMA: BearishJun 17, 20251 year ago
MACD: Sell SignalJun 16, 20251 year ago
RSI: OverboughtJun 5, 20251 year ago
SMA: BullishMay 30, 20251 year ago
MACD: Buy SignalMay 30, 20251 year ago
MACD: Sell SignalMay 7, 20251 year ago
SMA: BearishMay 6, 20251 year ago
SMA: BullishMay 2, 20251 year ago
SMA: BullishApr 23, 20251 year ago
MACD: Buy SignalMar 27, 20251 year ago
MACD: Sell SignalMar 5, 20251 year ago
MACD: Buy SignalFeb 19, 20251 year ago
MACD: Sell SignalFeb 3, 20251 year ago
SMA: BearishJan 29, 20251 year ago
SMA: BullishJan 28, 20251 year ago
RSI: OversoldDec 20, 20241 year ago
RSI: OversoldNov 25, 20241 year ago

Key statistics

Market cap
27.75M
Enterprise value
16.85M
Trailing P/E
0.00
Forward P/E
-2.35
PEG ratio
0.00
Price / sales
9.77
Price / book
0.00
EPS (TTM)
-0.58
Beta
1.34
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-253.60%
Revenue (TTM)
2.84M
Revenue growth
0.00%
Free cash flow
-20.98M
Total cash
16.41M
Total debt
5.83M
Return on equity
0.00%
Shares outstanding
8.70M
Short % of float
0.35%
50-day average
3.53
200-day average
4.07

Analyst view

Consensus: buy

Buy
Price target (mean) 21.33 +2949.4% upside
Target (low)
12.00
Target (mean)
21.33
Target (high)
39.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
  • Strong buy1
  • Buy2
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate -0.63333.

Earnings history

Financials — quick view

All financials
DARE Revenue — quarterly 187.55K
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
DARE Net income — quarterly -2.98M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
DARE EPS — quarterly -0.20
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

DARE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 2024-0.60-0.55+0.05+8.33%
Aug 12, 2024Jun 1, 2024-0.571.52+2.09+366.67%
May 14, 2024Mar 1, 2024-0.72-0.84-0.12-16.67%
Mar 28, 2024Dec 1, 2023-1.44-0.72+0.72+50.00%
Nov 9, 2023Sep 1, 2023-1.20-1.08+0.12+10.00%
Aug 10, 2023Jun 1, 2023-1.20-1.200.000.00%

Upgrades / downgrades

DARE analyst upgrades and downgrades
DateFirmActionFromTo
Dec 17, 2024HC Wainwright & Co.reitBuyBuy
Nov 15, 2024HC Wainwright & Co.reitBuyBuy
Oct 24, 2024HC Wainwright & Co.reitBuyBuy
Aug 16, 2024Jones TradingmainBuyBuy
Aug 14, 2024Maxim GroupdownBuyHold
May 15, 2024HC Wainwright & Co.reitBuyBuy

About Daré Bioscience, Inc.

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on DARE — it syncs with the Stock Master app.

Institution ownership

DARE institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc3.31%287,725917.84KSep 29, 2024
AMH Equity Ltd.1.15%100,000319.00KSep 29, 2024
Geode Capital Management, LLC1.02%89,060284.10KSep 29, 2024
Renaissance Technologies, LLC0.74%64,395205.42KSep 29, 2024
State Street Corporation0.27%23,51575.01KSep 29, 2024
Commonwealth Equity Services, LLC0.20%17,48655.78KSep 29, 2024

Fund ownership

DARE fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.37%205,801656.50KSep 29, 2024
Vanguard Extended Market Index Fund0.91%78,984251.96KSep 29, 2024
Fidelity Extended Market Index Fund0.56%48,543154.85KOct 30, 2024
Fidelity Total Market Index Fund0.18%15,46149.32KOct 30, 2024
Fidelity Series Total Market Index Fund0.14%11,77437.56KOct 30, 2024
Price (T.Rowe) U.S. Equities Trust0.12%10,49133.47KSep 29, 2024
Advertisement